Session Abstract – PMWC 2023 Silicon Valley

Track 2 - January 25 3.45 P.M.-4.30 P.M.


To make a lasting and meaningful impact within healthcare we need to understand the incentive structures and get them right. In this session, we will hear from academic and industry leaders as they share the challenges around collaboration and the unrealized potential of public-private partnerships in driving innovation.

 Session Chair Profile

Head of Commercial Partnerships, Syntropy

Biography
Justin Wildsmith brings a rich 22-year history of enabling scientific discovery at Merck across research, biopharma, international sales, and marketing as well as partnering roles. In his current role he is responsible for securing, implementing, and managing partner and customer alliances that align with Syntropy’s vision for continued growth. Prior to joining EMD Digital, Justin was most recently responsible for the partnerships and alliances franchise within Mercks Life Science research division where he led a team managing more than €270M in global partnership revenue. His history of global leadership includes forming, implementing, and managing alliances from strategy through execution.

Talk
Misaligned Incentives Across Public-Private Partnerships in Patient Health
To make a lasting and meaningful impact within healthcare we need to understand the incentive structures and get them right. In this session, we will hear from academic and industry leaders as they share the challenges around collaboration and the unrealized potential of public-private partnerships in driving innovation.


 Speaker Profile

Head of Academic Medicine, Amazon Web Services

Biography
Ken leads the AWS Academic Medicine Vertical which includes a team of Principal Trusted Advisors in Digital Health, Hospital Modernization, Precision Medicine, Clinical Care, and Informatics, and HealthTech sub-verticals, and a team of field-based and customer-facing Healthcare Executive Advisors. He has over 30 years of healthcare experience, including founding and taking public a cell and gene therapy company. Prior experience includes being a Chief Clinical Officer, President, and CEO for 10 years prior to joining AWS. Ken has a strong background in building and commercializing regulated products in the device, combination product, clinical software, and therapeutic biologics space.


 Speaker Profile

MD, Associate Professor, Medicine, Harvard Medical School, Interim Group Chair, Alliance for Clinical Trials in Oncology, Dana-Farber Cancer

Biography
Suzanne George, received her MD from the University of Massachusetts Medical School after earning a degree in chemistry from Harvard College. She completed her internal medicine training at the University of North Carolina at Chapel Hill and Tufts. She then completed a hematology/oncology fellowship at New England Medical Center/Tufts. Dr. George has spent her career focused on clinical trials and drug development in sarcomas, including key roles in the development of several compounds which have ultimately gained global regulatory approval as new standards of care in this field. Dr. George is also the Interim Group Chair of the Alliance for Clinical Trials in Oncology, a large NCI funded oncology clinical trials research base, part of the National Clinical Trials Network. In this capacity, she oversees the research direction of the group and is heavily involved in efforts to integrate data standards in oncology to improve clinical research, through enhanced inclusion and efficiency.


 Speaker Profile

MD, PHD, Vice Chancellor of Health Affairs, University of California

Biography
As Vice Chancellor of Health Affairs for the University of California, Dr. Steve Goldstein leads a $2.4 billion enterprise. With over 30 years of experience as a physician-scientist, pediatric cardiologist, and academic administrator, Goldstein focuses on improving the human condition through education, research and care. Goldstein holds an M.D. and a Ph.D. in immunology from Harvard University. His research has identified families of genes encoding ion channels, the genetic and mechanistic bases for sudden infant death syndrome in African Americans, inherited and drug-induced cardiac arrhythmias, skeletal muscle disorders and ischemic stroke. He has served as a scientific advisor to the National Institutes of Health for Nanomedicine and vice chair of the National Science Foundation Advisory Committee for Biological Sciences. A listing of his published works is available here: https://tinyurl.com/ycnqnwqt


 Speaker Profile

Head of Biomedical Partnerships and Strategy, Palantir

Biography
TBD